May/June 2017
Cost of Squamous Cell Cancer of the Head and Neck
June 22, 2017
Article
Original Research
The cost of squamous cell cancer of the head and neck is driven primarily by the end-of-life phase. Treatment costs increased following the approval of cetuximab.
Opportunities and Challenges With Value-Based Contracting
June 22, 2017
Article
Commentary
Given the need to provide patients with access to effective medications, it is likely that we will see more value-based contracts in the future; however, some key operational, communications, and regulatory barriers will need to be addressed first.
Payers' Views on the Heterogeneity of Treatment Effect in Oncology
June 22, 2017
Article
Original Research
When making coverage decisions in oncology, payers find difficulties in translating evidence on treatment effect heterogeneity into coverage policies.
It Is Time We Create a Pharmacy Benefit That Is Patient Centric
June 22, 2017
Article
From the Editor
The pharmacy benefit has begun to attract greater attention due to the increase in medications that are available and their cost. It is time we refocus on the needs of the patient and push ourselves and the benefit managers to evolve into a single integrated management and distribution model.
Assessing the Association Between Medication Adherence and Glycemic Control
June 13, 2017
Article
Original Research
Among a population of adult patients with type 2 diabetes, adherence to oral hypoglycemic medications is independently associated with poor glycemic control, even after adjusting for patient-level covariates.